225 related articles for article (PubMed ID: 18704630)
1. Glycosylation in bladder cancer.
Ohyama C
Int J Clin Oncol; 2008 Aug; 13(4):308-13. PubMed ID: 18704630
[TBL] [Abstract][Full Text] [Related]
2. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.
Hakomori S
Cancer Res; 1996 Dec; 56(23):5309-18. PubMed ID: 8968075
[TBL] [Abstract][Full Text] [Related]
3. Glycan changes: cancer metastasis and anti-cancer vaccines.
Li M; Song L; Qin X
J Biosci; 2010 Dec; 35(4):665-73. PubMed ID: 21289447
[TBL] [Abstract][Full Text] [Related]
4. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study.
Juhl BR
Dan Med Bull; 1994 Feb; 41(1):1-11. PubMed ID: 8187557
[TBL] [Abstract][Full Text] [Related]
5. Detection of a glycosphingolipid antigen in bladder cancer cells with monoclonal antibody MRG-1.
Kurimoto S; Moriyama N; Takata K; Nozawa S; Aso Y; Hirano H
Histochem J; 1995 Mar; 27(3):247-52. PubMed ID: 7797428
[TBL] [Abstract][Full Text] [Related]
6. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells.
Satoh M; Ito A; Nojiri H; Handa K; Numahata K; Ohyama C; Saito S; Hoshi S; Hakomori SI
Int J Oncol; 2001 Oct; 19(4):723-31. PubMed ID: 11562747
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines and carbohydrate epitopes.
Heimburg-Molinaro J; Lum M; Vijay G; Jain M; Almogren A; Rittenhouse-Olson K
Vaccine; 2011 Nov; 29(48):8802-26. PubMed ID: 21964054
[TBL] [Abstract][Full Text] [Related]
8. New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy.
Hakomori S
Cancer Cells; 1991 Dec; 3(12):461-70. PubMed ID: 1820092
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension.
Peixoto A; Fernandes E; Gaiteiro C; Lima L; Azevedo R; Soares J; Cotton S; Parreira B; Neves M; Amaro T; Tavares A; Teixeira F; Palmeira C; Rangel M; Silva AM; Reis CA; Santos LL; Oliveira MJ; Ferreira JA
Oncotarget; 2016 Sep; 7(39):63138-63157. PubMed ID: 27542232
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Glycosphingolipids in the Human Parathyroid and Thyroid Glands.
Säljö K; Thornell A; Jin C; Stålberg P; Norlén O; Teneberg S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208903
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of cancer-associated glycosylation changes.
Dall'Olio F; Malagolini N; Trinchera M; Chiricolo M
Front Biosci (Landmark Ed); 2012 Jan; 17(2):670-99. PubMed ID: 22201768
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive clinico-glycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells.
Misonou Y; Shida K; Korekane H; Seki Y; Noura S; Ohue M; Miyamoto Y
J Proteome Res; 2009 Jun; 8(6):2990-3005. PubMed ID: 19292502
[TBL] [Abstract][Full Text] [Related]
13. The C-type lectin L-SIGN differentially recognizes glycan antigens on egg glycosphingolipids and soluble egg glycoproteins from Schistosoma mansoni.
Meyer S; Tefsen B; Imberty A; Geyer R; van Die I
Glycobiology; 2007 Oct; 17(10):1104-19. PubMed ID: 17621595
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 interactions with glycosphingolipids.
Collins PM; Bum-Erdene K; Yu X; Blanchard H
J Mol Biol; 2014 Apr; 426(7):1439-51. PubMed ID: 24326249
[TBL] [Abstract][Full Text] [Related]
15. Ganglioside/glycosphingolipid turnover: new concepts.
Tettamanti G
Glycoconj J; 2004; 20(5):301-17. PubMed ID: 15229395
[TBL] [Abstract][Full Text] [Related]
16. N-acetylglucosaminyltransferase V and beta1-6 branching N-linked oligosaccharides are associated with good prognosis of patients with bladder cancer.
Ishimura H; Takahashi T; Nakagawa H; Nishimura S; Arai Y; Horikawa Y; Habuchi T; Miyoshi E; Kyan A; Hagisawa S; Ohyama C
Clin Cancer Res; 2006 Apr; 12(8):2506-11. PubMed ID: 16638859
[TBL] [Abstract][Full Text] [Related]
17. Novel carbohydrate specificity of the 16-kDa galectin from Caenorhabditis elegans: binding to blood group precursor oligosaccharides (type 1, type 2, Talpha, and Tbeta) and gangliosides.
Ahmed H; Bianchet MA; Amzel LM; Hirabayashi J; Kasai K; Giga-Hama Y; Tohda H; Vasta GR
Glycobiology; 2002 Aug; 12(8):451-61. PubMed ID: 12145186
[TBL] [Abstract][Full Text] [Related]
18. Altered Glycosylation in Progression and Management of Bladder Cancer.
Wilczak M; Surman M; Przybyło M
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110670
[TBL] [Abstract][Full Text] [Related]
19. Quantitative glycome analysis of N-glycan patterns in bladder cancer vs normal bladder cells using an integrated strategy.
Yang G; Tan Z; Lu W; Guo J; Yu H; Yu J; Sun C; Qi X; Li Z; Guan F
J Proteome Res; 2015 Feb; 14(2):639-53. PubMed ID: 25536294
[TBL] [Abstract][Full Text] [Related]
20. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.
Mitsuzuka K; Handa K; Satoh M; Arai Y; Hakomori S
J Biol Chem; 2005 Oct; 280(42):35545-53. PubMed ID: 16103120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
